![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FAM9B |
Gene summary for FAM9B |
![]() |
Gene information | Species | Human | Gene symbol | FAM9B | Gene ID | 171483 |
Gene name | family with sequence similarity 9 member B | |
Gene Alias | TEX39B | |
Cytomap | Xp22.31 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024RBV3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
171483 | FAM9B | NAFLD1 | Human | Liver | NAFLD | 3.32e-05 | 6.01e-01 | -0.04 |
171483 | FAM9B | S41 | Human | Liver | Cirrhotic | 4.33e-04 | 3.70e-01 | -0.0343 |
171483 | FAM9B | HCC1_Meng | Human | Liver | HCC | 2.93e-08 | 5.60e-03 | 0.0246 |
171483 | FAM9B | HCC2 | Human | Liver | HCC | 8.95e-04 | 3.47e-01 | 0.5341 |
171483 | FAM9B | HCC5 | Human | Liver | HCC | 8.17e-05 | 5.08e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM9B | SNV | Missense_Mutation | c.149G>T | p.Gly50Val | p.G50V | Q8IZU0 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-A2-A0T3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
FAM9B | SNV | Missense_Mutation | c.176N>A | p.Thr59Asn | p.T59N | Q8IZU0 | protein_coding | deleterious(0) | possibly_damaging(0.788) | TCGA-EW-A1PD-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | SD | |
FAM9B | SNV | Missense_Mutation | c.261G>C | p.Leu87Phe | p.L87F | Q8IZU0 | protein_coding | tolerated(0.15) | probably_damaging(0.961) | TCGA-C5-A8XI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
FAM9B | SNV | Missense_Mutation | c.434N>A | p.Arg145Lys | p.R145K | Q8IZU0 | protein_coding | deleterious(0.03) | possibly_damaging(0.694) | TCGA-Q1-A6DT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
FAM9B | SNV | Missense_Mutation | c.295N>C | p.Tyr99His | p.Y99H | Q8IZU0 | protein_coding | tolerated(0.37) | probably_damaging(0.961) | TCGA-A6-6652-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Targeted Molecular therapy | cetuximab | SD | |
FAM9B | SNV | Missense_Mutation | c.200N>T | p.Arg67Ile | p.R67I | Q8IZU0 | protein_coding | deleterious(0.01) | benign(0.117) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FAM9B | SNV | Missense_Mutation | c.62N>T | p.Arg21Ile | p.R21I | Q8IZU0 | protein_coding | deleterious(0.02) | possibly_damaging(0.766) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FAM9B | SNV | Missense_Mutation | c.112N>A | p.Glu38Lys | p.E38K | Q8IZU0 | protein_coding | tolerated(0.73) | possibly_damaging(0.636) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
FAM9B | SNV | Missense_Mutation | novel | c.437G>T | p.Ser146Ile | p.S146I | Q8IZU0 | protein_coding | tolerated(1) | probably_damaging(0.928) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
FAM9B | SNV | Missense_Mutation | novel | c.196A>C | p.Lys66Gln | p.K66Q | Q8IZU0 | protein_coding | deleterious(0.02) | benign(0.053) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |